Fusion Gene Studies
in Kim Lab

FusionBase FusionGDB FusionGDB2 FusionPDB FusionNeoAntigen FusionAI FusionNW FGviewer Publication Contact
FusionGDB Logo

Home

Download

Statistics

Examples

Help

Contact
Center for Computational Systems Medicine
leaf

Fusion Gene Summary

leaf

Fusion Gene ORF analysis

leaf

Fusion Genomic Features

leaf

Fusion Protein Features

leaf

Fusion Gene Sequence

leaf

Fusion Gene PPI analysis

leaf

Related Drugs

leaf

Related Diseases

Fusion gene:ATIC-ALK (FusionGDB2 ID:HG471TG238)

Fusion Gene Summary for ATIC-ALK

check button Fusion gene summary
Fusion gene informationFusion gene name: ATIC-ALK
Fusion gene ID: hg471tg238
HgeneTgene
Gene symbol

ATIC

ALK

Gene ID

471

238

Gene name5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolaseALK receptor tyrosine kinase
SynonymsAICAR|AICARFT|HEL-S-70p|IMPCHASE|PURHCD246|NBLST3
Cytomap('ATIC')('ALK')

2q35

2p23.2-p23.1

Type of geneprotein-codingprotein-coding
Descriptionbifunctional purine biosynthesis protein PURH5-aminoimidazole-4-carboxamide-1-beta-D-ribonucleotide transformylase/inosinicaseAICAR formyltransferase/IMP cyclohydrolase bifunctional enzymeAICARFT/IMPCHASEepididymis secretory sperm binding protein Li 7ALK tyrosine kinase receptorCD246 antigenanaplastic lymphoma receptor tyrosine kinasemutant anaplastic lymphoma kinase
Modification date2020031320200329
UniProtAcc

P31939

Q9UM73

Ensembl transtripts involved in fusion geneENST00000236959, ENST00000435675, 
ENST00000540518, 
Fusion gene scores* DoF score9 X 9 X 4=32456 X 74 X 20=82880
# samples 957
** MAII scorelog2(9/324*10)=-1.84799690655495
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0		log2(57/82880*10)=-7.18391827352181
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Context

PubMed: ATIC [Title/Abstract] AND ALK [Title/Abstract] AND fusion [Title/Abstract]

Most frequent breakpoint
Anticipated loss of major functional domain due to fusion event.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
TgeneALK

GO:0016310

phosphorylation

9174053

TgeneALK

GO:0046777

protein autophosphorylation

9174053



check button Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0)
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
SourceDiseaseSampleHgeneHchrHbpHstrandTgeneTchrTbpTstrand
ChimerKB3..ATICchr2

216176678

+ALKchr2

29445274

-
ChimerKB3..ATICchr2

216191701

+ALKchr2

29446394

-


Top

Fusion Gene ORF analysis for ATIC-ALK

check button Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
ORFHenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrand
5CDS-intronENST00000236959ENST00000431873ATICchr2

216191701

+ALKchr2

29446394

-
5CDS-intronENST00000236959ENST00000498037ATICchr2

216191701

+ALKchr2

29446394

-
5CDS-intronENST00000435675ENST00000431873ATICchr2

216191701

+ALKchr2

29446394

-
5CDS-intronENST00000435675ENST00000498037ATICchr2

216191701

+ALKchr2

29446394

-
5CDS-intronENST00000540518ENST00000431873ATICchr2

216191701

+ALKchr2

29446394

-
5CDS-intronENST00000540518ENST00000498037ATICchr2

216191701

+ALKchr2

29446394

-
5UTR-3CDSENST00000236959ENST00000389048ATICchr2

216176678

+ALKchr2

29445274

-
5UTR-intronENST00000236959ENST00000431873ATICchr2

216176678

+ALKchr2

29445274

-
5UTR-intronENST00000236959ENST00000498037ATICchr2

216176678

+ALKchr2

29445274

-
In-frameENST00000236959ENST00000389048ATICchr2

216191701

+ALKchr2

29446394

-
In-frameENST00000435675ENST00000389048ATICchr2

216191701

+ALKchr2

29446394

-
In-frameENST00000540518ENST00000389048ATICchr2

216191701

+ALKchr2

29446394

-
intron-3CDSENST00000435675ENST00000389048ATICchr2

216176678

+ALKchr2

29445274

-
intron-3CDSENST00000540518ENST00000389048ATICchr2

216176678

+ALKchr2

29445274

-
intron-intronENST00000435675ENST00000431873ATICchr2

216176678

+ALKchr2

29445274

-
intron-intronENST00000435675ENST00000498037ATICchr2

216176678

+ALKchr2

29445274

-
intron-intronENST00000540518ENST00000431873ATICchr2

216176678

+ALKchr2

29445274

-
intron-intronENST00000540518ENST00000498037ATICchr2

216176678

+ALKchr2

29445274

-

check buttonORFfinder result based on the fusion transcript sequence of in-frame fusion genes.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)		BP loci
(transcript)		Predicted start
(transcript)		Predicted stop
(transcript)		Seq length
(amino acids)
ENST00000236959ATICchr2216191701+ENST00000389048ALKchr229446394-315510142662704812
ENST00000540518ATICchr2216191701+ENST00000389048ALKchr229446394-31299882792678799
ENST00000435675ATICchr2216191701+ENST00000389048ALKchr229446394-321710763912766791

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score

Top

Fusion Genomic Features for ATIC-ALK


check buttonFusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints.
HgeneHchrHbpHstrandTgeneTchrTbpTstrand1-pp (fusion gene breakpoint)


Top

Fusion Protein Features for ATIC-ALK


check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr2:/chr2:)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonMain function of each fusion partner protein. (from UniProt)
HgeneTgene
ATIC

P31939

ALK

Q9UM73

FUNCTION: Bifunctional enzyme that catalyzes the last two steps of purine biosynthesis (PubMed:11948179, PubMed:14756554). Acts as a transformylase that incorporates a formyl group to the AMP analog AICAR (5-amino-1-(5-phospho-beta-D-ribosyl)imidazole-4-carboxamide) to produce the intermediate formyl-AICAR (FAICAR) (PubMed:9378707, PubMed:11948179, PubMed:10985775). Can use both 10-formyldihydrofolate and 10-formyltetrahydrofolate as the formyl donor in this reaction (PubMed:10985775). Also catalyzes the cyclization of FAICAR to IMP (PubMed:11948179, PubMed:14756554). Is able to convert thio-AICAR to 6-mercaptopurine ribonucleotide, an inhibitor of purine biosynthesis used in the treatment of human leukemias (PubMed:10985775). Promotes insulin receptor/INSR autophosphorylation and is involved in INSR internalization (PubMed:25687571). {ECO:0000269|PubMed:10985775, ECO:0000269|PubMed:11948179, ECO:0000269|PubMed:14756554, ECO:0000269|PubMed:25687571, ECO:0000269|PubMed:9378707}.FUNCTION: Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK. Thinness gene involved in the resistance to weight gain: in hypothalamic neurons, controls energy expenditure acting as a negative regulator of white adipose tissue lipolysis and sympathetic tone to fine-tune energy homeostasis (By similarity). {ECO:0000250|UniProtKB:P97793, ECO:0000269|PubMed:11121404, ECO:0000269|PubMed:11278720, ECO:0000269|PubMed:11387242, ECO:0000269|PubMed:11809760, ECO:0000269|PubMed:12107166, ECO:0000269|PubMed:12122009, ECO:0000269|PubMed:15226403, ECO:0000269|PubMed:15908427, ECO:0000269|PubMed:16317043, ECO:0000269|PubMed:16878150, ECO:0000269|PubMed:17274988}.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at

download page


* Minus value of BPloci means that the break pointn is located before the CDS.
- In-frame and retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

- In-frame and not-retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note


Top

Fusion Gene Sequence for ATIC-ALK


check button For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones.
>7628_7628_1_ATIC-ALK_ATIC_chr2_216191701_ENST00000236959_ALK_chr2_29446394_ENST00000389048_length(transcript)=3155nt_BP=1014nt
ACTTTGGGGTCGTGGGCAGATCGCTGGCTCCCACGCCTGGACTTCGGGATCGCAGGCAGGATCCCTTCCAGCCCAAGCACTCCGCCCAGG
CGCGCCAGGCAGAGCCCCACCCCATCCCGCCGTTCCCTTCAGCCCCGGGGCGCGGATCTTGCATCTGAAACTGAGCAGAGCAGGGCGCCG
GGCAGGGCCGGCGGGCCACGTGATAAGCCCGGAAACAGCTCCGCCCCCTCGCTTCCTGAGCCGCCACATCCCGGCAGCCCTCCTACCTGC
GCACGTGGTGCCGCCGCTGCTGCCTCCCGCTCGCCCTGAACCCAGTGCCTGCAGCCATGGCTCCCGGCCAGCTCGCCTTATTTAGTGTCT
CTGACAAAACCGGCCTTGTGGAATTTGCAAGAAACCTGACCGCTCTTGGTTTGAATCTGGTCGCTTCCGGAGGGACTGCAAAAGCTCTCA
GGGATGCTGGTCTGGCAGTCAGAGATGTCTCTGAGTTGACGGGATTTCCTGAAATGTTGGGGGGACGTGTGAAAACTTTGCATCCTGCAG
TCCATGCTGGAATCCTAGCTCGTAATATTCCAGAAGATAATGCTGACATGGCCAGACTTGATTTCAATCTTATAAGAGTTGTTGCCTGCA
ATCTCTATCCCTTTGTAAAGACAGTGGCTTCTCCAGGTGTAACTGTTGAGGAGGCTGTGGAGCAAATTGACATTGGTGGAGTAACCTTAC
TGAGAGCTGCAGCCAAAAACCACGCTCGAGTGACAGTGGTGTGTGAACCAGAGGACTATGTGGTGGTGTCCACGGAGATGCAGAGCTCCG
AGAGTAAGGACACCTCCTTGGAGACTAGACGCCAGTTAGCCTTGAAGGCATTCACTCATACGGCACAATATGATGAAGCAATTTCAGATT
ATTTCAGGAAACAGTACAGCAAAGGCGTATCTCAGATGCCCTTGAGATATGGAATGAACCCACATCAGACCCCTGCCCAGCTGTACACAC
TGCAGCCCAAGCTTCCCATCACAGTGTACCGCCGGAAGCACCAGGAGCTGCAAGCCATGCAGATGGAGCTGCAGAGCCCTGAGTACAAGC
TGAGCAAGCTCCGCACCTCGACCATCATGACCGACTACAACCCCAACTACTGCTTTGCTGGCAAGACCTCCTCCATCAGTGACCTGAAGG
AGGTGCCGCGGAAAAACATCACCCTCATTCGGGGTCTGGGCCATGGCGCCTTTGGGGAGGTGTATGAAGGCCAGGTGTCCGGAATGCCCA
ACGACCCAAGCCCCCTGCAAGTGGCTGTGAAGACGCTGCCTGAAGTGTGCTCTGAACAGGACGAACTGGATTTCCTCATGGAAGCCCTGA
TCATCAGCAAATTCAACCACCAGAACATTGTTCGCTGCATTGGGGTGAGCCTGCAATCCCTGCCCCGGTTCATCCTGCTGGAGCTCATGG
CGGGGGGAGACCTCAAGTCCTTCCTCCGAGAGACCCGCCCTCGCCCGAGCCAGCCCTCCTCCCTGGCCATGCTGGACCTTCTGCACGTGG
CTCGGGACATTGCCTGTGGCTGTCAGTATTTGGAGGAAAACCACTTCATCCACCGAGACATTGCTGCCAGAAACTGCCTCTTGACCTGTC
CAGGCCCTGGAAGAGTGGCCAAGATTGGAGACTTCGGGATGGCCCGAGACATCTACAGGGCGAGCTACTATAGAAAGGGAGGCTGTGCCA
TGCTGCCAGTTAAGTGGATGCCCCCAGAGGCCTTCATGGAAGGAATATTCACTTCTAAAACAGACACATGGTCCTTTGGAGTGCTGCTAT
GGGAAATCTTTTCTCTTGGATATATGCCATACCCCAGCAAAAGCAACCAGGAAGTTCTGGAGTTTGTCACCAGTGGAGGCCGGATGGACC
CACCCAAGAACTGCCCTGGGCCTGTATACCGGATAATGACTCAGTGCTGGCAACATCAGCCTGAAGACAGGCCCAACTTTGCCATCATTT
TGGAGAGGATTGAATACTGCACCCAGGACCCGGATGTAATCAACACCGCTTTGCCGATAGAATATGGTCCACTTGTGGAAGAGGAAGAGA
AAGTGCCTGTGAGGCCCAAGGACCCTGAGGGGGTTCCTCCTCTCCTGGTCTCTCAACAGGCAAAACGGGAGGAGGAGCGCAGCCCAGCTG
CCCCACCACCTCTGCCTACCACCTCCTCTGGCAAGGCTGCAAAGAAACCCACAGCTGCAGAGATCTCTGTTCGAGTCCCTAGAGGGCCGG
CCGTGGAAGGGGGACACGTGAATATGGCATTCTCTCAGTCCAACCCTCCTTCGGAGTTGCACAAGGTCCACGGATCCAGAAACAAGCCCA
CCAGCTTGTGGAACCCAACGTACGGCTCCTGGTTTACAGAGAAACCCACCAAAAAGAATAATCCTATAGCAAAGAAGGAGCCACACGACA
GGGGTAACCTGGGGCTGGAGGGAAGCTGTACTGTCCCACCTAACGTTGCAACTGGGAGACTTCCGGGGGCCTCACTGCTCCTAGAGCCCT
CTTCGCTGACTGCCAATATGAAGGAGGTACCTCTGTTCAGGCTACGTCACTTCCCTTGTGGGAATGTCAATTACGGCTACCAGCAACAGG
GCTTGCCCTTAGAAGCCGCTACTGCCCCTGGAGCTGGTCATTACGAGGATACCATTCTGAAAAGCAAGAATAGCATGAACCAGCCTGGGC
CCTGAGCTCGGTCGCACACTCACTTCTCTTCCTTGGGATCCCTAAGACCGTGGAGGAGAGAGAGGCAATGGCTCCTTCACAAACCAGAGA
CCAAATGTCACGTTTTGTTTTGTGCCAACCTATTTTGAAGTACCACCAAAAAAGCTGTATTTTGAAAATGCTTTAGAAAGGTTTTGAGCA
TGGGTTCATCCTATTCTTTCGAAAGAAGAAAATATCATAAAAATGAGTGATAAATACAAGGCCCAGATGTGGTTGCATAAGGTTTTTATG
CATGTTTGTTGTATACTTCCTTATGCTTCTTTCAAATTGTGTGTGCTCTGCTTCAATGTAGTCAGAATTAGCTGCTTCTATGTTTCATAG
TTGGGGTCATAGATGTTTCCTTGCCTTGTTGATGTGGACATGAGCCATTTGAGGGGAGAGGGAACGGAAATAAAGGAGTTATTTGTAATG

>7628_7628_1_ATIC-ALK_ATIC_chr2_216191701_ENST00000236959_ALK_chr2_29446394_ENST00000389048_length(amino acids)=812AA_BP=249
MRTWCRRCCLPLALNPVPAAMAPGQLALFSVSDKTGLVEFARNLTALGLNLVASGGTAKALRDAGLAVRDVSELTGFPEMLGGRVKTLHP
AVHAGILARNIPEDNADMARLDFNLIRVVACNLYPFVKTVASPGVTVEEAVEQIDIGGVTLLRAAAKNHARVTVVCEPEDYVVVSTEMQS
SESKDTSLETRRQLALKAFTHTAQYDEAISDYFRKQYSKGVSQMPLRYGMNPHQTPAQLYTLQPKLPITVYRRKHQELQAMQMELQSPEY
KLSKLRTSTIMTDYNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEA
LIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLT
CPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRM
DPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSP
AAPPPLPTTSSGKAAKKPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPH
DRGNLGLEGSCTVPPNVATGRLPGASLLLEPSSLTANMKEVPLFRLRHFPCGNVNYGYQQQGLPLEAATAPGAGHYEDTILKSKNSMNQP

--------------------------------------------------------------
>7628_7628_2_ATIC-ALK_ATIC_chr2_216191701_ENST00000435675_ALK_chr2_29446394_ENST00000389048_length(transcript)=3217nt_BP=1076nt
GTGGTGCCGCCGCTGCTGCCTCCCGCTCGCCCTGAACCCAGTGCCTGCAGCCATGGCTCCCGGCCAGCTCGGTGAGGCCCTAGCGGAGCG
GCGCGGTCTGCGTCCTCGCCTGCGGCCCCCCACGCTCCCGCCTTGGCGGCGGCCGGCGGGACCCGGCACTGCAGGGGCGGCGCTGCGGGA
TTGAAAGCCAGCGTCCCCGCTCCCCGGCCGGGCCGCAGCCTGCGTGGGGCCCGCCTTAGAGCAGCTCGCGGGTGTAAGACCTGGGGAGGC
CCGGACCAGGCCTGCGAACGCAGGGTCCAGGTGCTGGCCTTGCGATTCGAGAATCTCCTCCCCCAGACCCTCCCAAGGCCTTGCAGAACA
CAGTGCAATGTGCTGCGAATCATGAGAAAAAATGTCTTCTCTTTCAGCCTTATTTAGTGTCTCTGACAAAACCGGCCTTGTGGAATTTGC
AAGAAACCTGACCGCTCTTGGTTTGAATCTGGTCGCTTCCGGAGGGACTGCAAAAGCTCTCAGGGATGCTGGTCTGGCAGTCAGAGATGT
CTCTGAGTTGACGGGATTTCCTGAAATGTTGGGGGGACGTGTGAAAACTTTGCATCCTGCAGTCCATGCTGGAATCCTAGCTCGTAATAT
TCCAGAAGATAATGCTGACATGGCCAGACTTGATTTCAATCTTATAAGAGTTGTTGCCTGCAATCTCTATCCCTTTGTAAAGACAGTGGC
TTCTCCAGGTGTAACTGTTGAGGAGGCTGTGGAGCAAATTGACATTGGTGGAGTAACCTTACTGAGAGCTGCAGCCAAAAACCACGCTCG
AGTGACAGTGGTGTGTGAACCAGAGGACTATGTGGTGGTGTCCACGGAGATGCAGAGCTCCGAGAGTAAGGACACCTCCTTGGAGACTAG
ACGCCAGTTAGCCTTGAAGGCATTCACTCATACGGCACAATATGATGAAGCAATTTCAGATTATTTCAGGAAACAGTACAGCAAAGGCGT
ATCTCAGATGCCCTTGAGATATGGAATGAACCCACATCAGACCCCTGCCCAGCTGTACACACTGCAGCCCAAGCTTCCCATCACAGTGTA
CCGCCGGAAGCACCAGGAGCTGCAAGCCATGCAGATGGAGCTGCAGAGCCCTGAGTACAAGCTGAGCAAGCTCCGCACCTCGACCATCAT
GACCGACTACAACCCCAACTACTGCTTTGCTGGCAAGACCTCCTCCATCAGTGACCTGAAGGAGGTGCCGCGGAAAAACATCACCCTCAT
TCGGGGTCTGGGCCATGGCGCCTTTGGGGAGGTGTATGAAGGCCAGGTGTCCGGAATGCCCAACGACCCAAGCCCCCTGCAAGTGGCTGT
GAAGACGCTGCCTGAAGTGTGCTCTGAACAGGACGAACTGGATTTCCTCATGGAAGCCCTGATCATCAGCAAATTCAACCACCAGAACAT
TGTTCGCTGCATTGGGGTGAGCCTGCAATCCCTGCCCCGGTTCATCCTGCTGGAGCTCATGGCGGGGGGAGACCTCAAGTCCTTCCTCCG
AGAGACCCGCCCTCGCCCGAGCCAGCCCTCCTCCCTGGCCATGCTGGACCTTCTGCACGTGGCTCGGGACATTGCCTGTGGCTGTCAGTA
TTTGGAGGAAAACCACTTCATCCACCGAGACATTGCTGCCAGAAACTGCCTCTTGACCTGTCCAGGCCCTGGAAGAGTGGCCAAGATTGG
AGACTTCGGGATGGCCCGAGACATCTACAGGGCGAGCTACTATAGAAAGGGAGGCTGTGCCATGCTGCCAGTTAAGTGGATGCCCCCAGA
GGCCTTCATGGAAGGAATATTCACTTCTAAAACAGACACATGGTCCTTTGGAGTGCTGCTATGGGAAATCTTTTCTCTTGGATATATGCC
ATACCCCAGCAAAAGCAACCAGGAAGTTCTGGAGTTTGTCACCAGTGGAGGCCGGATGGACCCACCCAAGAACTGCCCTGGGCCTGTATA
CCGGATAATGACTCAGTGCTGGCAACATCAGCCTGAAGACAGGCCCAACTTTGCCATCATTTTGGAGAGGATTGAATACTGCACCCAGGA
CCCGGATGTAATCAACACCGCTTTGCCGATAGAATATGGTCCACTTGTGGAAGAGGAAGAGAAAGTGCCTGTGAGGCCCAAGGACCCTGA
GGGGGTTCCTCCTCTCCTGGTCTCTCAACAGGCAAAACGGGAGGAGGAGCGCAGCCCAGCTGCCCCACCACCTCTGCCTACCACCTCCTC
TGGCAAGGCTGCAAAGAAACCCACAGCTGCAGAGATCTCTGTTCGAGTCCCTAGAGGGCCGGCCGTGGAAGGGGGACACGTGAATATGGC
ATTCTCTCAGTCCAACCCTCCTTCGGAGTTGCACAAGGTCCACGGATCCAGAAACAAGCCCACCAGCTTGTGGAACCCAACGTACGGCTC
CTGGTTTACAGAGAAACCCACCAAAAAGAATAATCCTATAGCAAAGAAGGAGCCACACGACAGGGGTAACCTGGGGCTGGAGGGAAGCTG
TACTGTCCCACCTAACGTTGCAACTGGGAGACTTCCGGGGGCCTCACTGCTCCTAGAGCCCTCTTCGCTGACTGCCAATATGAAGGAGGT
ACCTCTGTTCAGGCTACGTCACTTCCCTTGTGGGAATGTCAATTACGGCTACCAGCAACAGGGCTTGCCCTTAGAAGCCGCTACTGCCCC
TGGAGCTGGTCATTACGAGGATACCATTCTGAAAAGCAAGAATAGCATGAACCAGCCTGGGCCCTGAGCTCGGTCGCACACTCACTTCTC
TTCCTTGGGATCCCTAAGACCGTGGAGGAGAGAGAGGCAATGGCTCCTTCACAAACCAGAGACCAAATGTCACGTTTTGTTTTGTGCCAA
CCTATTTTGAAGTACCACCAAAAAAGCTGTATTTTGAAAATGCTTTAGAAAGGTTTTGAGCATGGGTTCATCCTATTCTTTCGAAAGAAG
AAAATATCATAAAAATGAGTGATAAATACAAGGCCCAGATGTGGTTGCATAAGGTTTTTATGCATGTTTGTTGTATACTTCCTTATGCTT
CTTTCAAATTGTGTGTGCTCTGCTTCAATGTAGTCAGAATTAGCTGCTTCTATGTTTCATAGTTGGGGTCATAGATGTTTCCTTGCCTTG

>7628_7628_2_ATIC-ALK_ATIC_chr2_216191701_ENST00000435675_ALK_chr2_29446394_ENST00000389048_length(amino acids)=791AA_BP=228
MSSLSALFSVSDKTGLVEFARNLTALGLNLVASGGTAKALRDAGLAVRDVSELTGFPEMLGGRVKTLHPAVHAGILARNIPEDNADMARL
DFNLIRVVACNLYPFVKTVASPGVTVEEAVEQIDIGGVTLLRAAAKNHARVTVVCEPEDYVVVSTEMQSSESKDTSLETRRQLALKAFTH
TAQYDEAISDYFRKQYSKGVSQMPLRYGMNPHQTPAQLYTLQPKLPITVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFA
GKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQS
LPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYR
ASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQ
PEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAA
EISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGR

--------------------------------------------------------------
>7628_7628_3_ATIC-ALK_ATIC_chr2_216191701_ENST00000540518_ALK_chr2_29446394_ENST00000389048_length(transcript)=3129nt_BP=988nt
AGCCCTCCTACCTGCGCACGTGGTGCCGCCGCTGCTGCCTCCCGCTCGCCCTGAACCCAGTGCCTGCAGCCATGGCTCCCGGCCAGCTCG
GTGAGGCCCTAGCGGAGCGGCGCGGTCTGCGTCCTCGCCTGCGGCCCCCCACGCTCCCGCCTTGGCGGCGGCCGGCGGGACCCGGCACTG
CAGGGGCGGCGCTGCGGGATTGAAAGCCAGCGTCCCCGCTCCCCGGCCGGGCCGCAGCCTGCGTGGGGCCCGCCTTAGAGCAGCTCGCGG
GTGTAAGACCTGGGGAGGCCCGGACCAGGCCTGCGAACGCAGGGTCCAGCCTTATTTAGTGTCTCTGACAAAACCGGCCTTGTGGAATTT
GCAAGAAACCTGACCGCTCTTGGTTTGAATCTGGTCGCTTCCGGAGGGACTGCAAAAGCTCTCAGGGATGCTGGTCTGGCAGTCAGAGAT
GTCTCTGAGTTGACGGGATTTCCTGAAATGTTGGGGGGACGTGTGAAAACTTTGCATCCTGCAGTCCATGCTGGAATCCTAGCTCGTAAT
ATTCCAGAAGATAATGCTGACATGGCCAGACTTGATTTCAATCTTATAAGAGTTGTTGCCTGCAATCTCTATCCCTTTGTAAAGACAGTG
GCTTCTCCAGGTGTAACTGTTGAGGAGGCTGTGGAGCAAATTGACATTGGTGGAGTAACCTTACTGAGAGCTGCAGCCAAAAACCACGCT
CGAGTGACAGTGGTGTGTGAACCAGAGGACTATGTGGTGGTGTCCACGGAGATGCAGAGCTCCGAGAGTAAGGACACCTCCTTGGAGACT
AGACGCCAGTTAGCCTTGAAGGCATTCACTCATACGGCACAATATGATGAAGCAATTTCAGATTATTTCAGGAAACAGTACAGCAAAGGC
GTATCTCAGATGCCCTTGAGATATGGAATGAACCCACATCAGACCCCTGCCCAGCTGTACACACTGCAGCCCAAGCTTCCCATCACAGTG
TACCGCCGGAAGCACCAGGAGCTGCAAGCCATGCAGATGGAGCTGCAGAGCCCTGAGTACAAGCTGAGCAAGCTCCGCACCTCGACCATC
ATGACCGACTACAACCCCAACTACTGCTTTGCTGGCAAGACCTCCTCCATCAGTGACCTGAAGGAGGTGCCGCGGAAAAACATCACCCTC
ATTCGGGGTCTGGGCCATGGCGCCTTTGGGGAGGTGTATGAAGGCCAGGTGTCCGGAATGCCCAACGACCCAAGCCCCCTGCAAGTGGCT
GTGAAGACGCTGCCTGAAGTGTGCTCTGAACAGGACGAACTGGATTTCCTCATGGAAGCCCTGATCATCAGCAAATTCAACCACCAGAAC
ATTGTTCGCTGCATTGGGGTGAGCCTGCAATCCCTGCCCCGGTTCATCCTGCTGGAGCTCATGGCGGGGGGAGACCTCAAGTCCTTCCTC
CGAGAGACCCGCCCTCGCCCGAGCCAGCCCTCCTCCCTGGCCATGCTGGACCTTCTGCACGTGGCTCGGGACATTGCCTGTGGCTGTCAG
TATTTGGAGGAAAACCACTTCATCCACCGAGACATTGCTGCCAGAAACTGCCTCTTGACCTGTCCAGGCCCTGGAAGAGTGGCCAAGATT
GGAGACTTCGGGATGGCCCGAGACATCTACAGGGCGAGCTACTATAGAAAGGGAGGCTGTGCCATGCTGCCAGTTAAGTGGATGCCCCCA
GAGGCCTTCATGGAAGGAATATTCACTTCTAAAACAGACACATGGTCCTTTGGAGTGCTGCTATGGGAAATCTTTTCTCTTGGATATATG
CCATACCCCAGCAAAAGCAACCAGGAAGTTCTGGAGTTTGTCACCAGTGGAGGCCGGATGGACCCACCCAAGAACTGCCCTGGGCCTGTA
TACCGGATAATGACTCAGTGCTGGCAACATCAGCCTGAAGACAGGCCCAACTTTGCCATCATTTTGGAGAGGATTGAATACTGCACCCAG
GACCCGGATGTAATCAACACCGCTTTGCCGATAGAATATGGTCCACTTGTGGAAGAGGAAGAGAAAGTGCCTGTGAGGCCCAAGGACCCT
GAGGGGGTTCCTCCTCTCCTGGTCTCTCAACAGGCAAAACGGGAGGAGGAGCGCAGCCCAGCTGCCCCACCACCTCTGCCTACCACCTCC
TCTGGCAAGGCTGCAAAGAAACCCACAGCTGCAGAGATCTCTGTTCGAGTCCCTAGAGGGCCGGCCGTGGAAGGGGGACACGTGAATATG
GCATTCTCTCAGTCCAACCCTCCTTCGGAGTTGCACAAGGTCCACGGATCCAGAAACAAGCCCACCAGCTTGTGGAACCCAACGTACGGC
TCCTGGTTTACAGAGAAACCCACCAAAAAGAATAATCCTATAGCAAAGAAGGAGCCACACGACAGGGGTAACCTGGGGCTGGAGGGAAGC
TGTACTGTCCCACCTAACGTTGCAACTGGGAGACTTCCGGGGGCCTCACTGCTCCTAGAGCCCTCTTCGCTGACTGCCAATATGAAGGAG
GTACCTCTGTTCAGGCTACGTCACTTCCCTTGTGGGAATGTCAATTACGGCTACCAGCAACAGGGCTTGCCCTTAGAAGCCGCTACTGCC
CCTGGAGCTGGTCATTACGAGGATACCATTCTGAAAAGCAAGAATAGCATGAACCAGCCTGGGCCCTGAGCTCGGTCGCACACTCACTTC
TCTTCCTTGGGATCCCTAAGACCGTGGAGGAGAGAGAGGCAATGGCTCCTTCACAAACCAGAGACCAAATGTCACGTTTTGTTTTGTGCC
AACCTATTTTGAAGTACCACCAAAAAAGCTGTATTTTGAAAATGCTTTAGAAAGGTTTTGAGCATGGGTTCATCCTATTCTTTCGAAAGA
AGAAAATATCATAAAAATGAGTGATAAATACAAGGCCCAGATGTGGTTGCATAAGGTTTTTATGCATGTTTGTTGTATACTTCCTTATGC
TTCTTTCAAATTGTGTGTGCTCTGCTTCAATGTAGTCAGAATTAGCTGCTTCTATGTTTCATAGTTGGGGTCATAGATGTTTCCTTGCCT

>7628_7628_3_ATIC-ALK_ATIC_chr2_216191701_ENST00000540518_ALK_chr2_29446394_ENST00000389048_length(amino acids)=799AA_BP=236
MGRPGPGLRTQGPALFSVSDKTGLVEFARNLTALGLNLVASGGTAKALRDAGLAVRDVSELTGFPEMLGGRVKTLHPAVHAGILARNIPE
DNADMARLDFNLIRVVACNLYPFVKTVASPGVTVEEAVEQIDIGGVTLLRAAAKNHARVTVVCEPEDYVVVSTEMQSSESKDTSLETRRQ
LALKAFTHTAQYDEAISDYFRKQYSKGVSQMPLRYGMNPHQTPAQLYTLQPKLPITVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTD
YNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVR
CIGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDF
GMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRI
MTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGK
AAKKPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTV

--------------------------------------------------------------

Top

Fusion Gene PPI Analysis for ATIC-ALK


check button Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in

ChiPPI page.


check button Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160)
HgeneHgene's interactorsTgeneTgene's interactors


check button - Retained PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenStill interaction with


check button - Lost PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with


check button - Retained PPIs, but lost function due to frame-shift fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with


Top

Related Drugs for ATIC-ALK


check button Drugs targeting genes involved in this fusion gene.
(DrugBank Version 5.1.8 2021-05-08)
PartnerGeneUniProtAccDrugBank IDDrug nameDrug activityDrug typeDrug status
HgeneATICP31939DB00563MethotrexateInhibitorSmall moleculeApproved
HgeneATICP31939DB00563MethotrexateInhibitorSmall moleculeApproved
HgeneATICP31939DB00563MethotrexateInhibitorSmall moleculeApproved
HgeneATICP31939DB00642PemetrexedInhibitorSmall moleculeApproved|Investigational
HgeneATICP31939DB00642PemetrexedInhibitorSmall moleculeApproved|Investigational
HgeneATICP31939DB00642PemetrexedInhibitorSmall moleculeApproved|Investigational
TgeneALKQ9UM73DB08865CrizotinibInhibitorSmall moleculeApproved
TgeneALKQ9UM73DB09063CeritinibAntagonistSmall moleculeApproved
TgeneALKQ9UM73DB11363AlectinibInhibitorSmall moleculeApproved|Investigational
TgeneALKQ9UM73DB12010FostamatinibInhibitorSmall moleculeApproved|Investigational
TgeneALKQ9UM73DB12130LorlatinibInhibitorSmall moleculeApproved|Investigational
TgeneALKQ9UM73DB12141GilteritinibInhibitorSmall moleculeApproved|Investigational
TgeneALKQ9UM73DB12267BrigatinibInhibitorSmall moleculeApproved|Investigational

Top

Related Diseases for ATIC-ALK


check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
HgeneATICC0001787Osteoporosis, Age-Related1CTD_human
HgeneATICC0003873Rheumatoid Arthritis1CTD_human
HgeneATICC0013221Drug toxicity1CTD_human
HgeneATICC0029456Osteoporosis1CTD_human
HgeneATICC0029459Osteoporosis, Senile1CTD_human
HgeneATICC0041755Adverse reaction to drug1CTD_human
HgeneATICC0155003Blindness, Transient1CTD_human
HgeneATICC0221473Blindness, Hysterical1CTD_human
HgeneATICC0271215Blindness, Legal1CTD_human
HgeneATICC0339730Blindness, Acquired1CTD_human
HgeneATICC0376288Amaurosis1CTD_human
HgeneATICC0456909Blindness1CTD_human
HgeneATICC0750958Blindness, Monocular1CTD_human
HgeneATICC0751406Post-Traumatic Osteoporosis1CTD_human
HgeneATICC1837530AICAR Transformylase Inosine Monophosphate Cyclohydrolase Deficiency1CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
HgeneATICC1879328Blindness both eyes NOS (disorder)1CTD_human
HgeneATICC3714756Intellectual Disability1GENOMICS_ENGLAND
TgeneC0007131Non-Small Cell Lung Carcinoma28CGI;CTD_human
TgeneC0027819Neuroblastoma13CGI;CTD_human;ORPHANET
TgeneC0152013Adenocarcinoma of lung (disorder)8CGI;CTD_human
TgeneC2751681NEUROBLASTOMA, SUSCEPTIBILITY TO, 38CLINGEN;UNIPROT
TgeneC0206180Ki-1+ Anaplastic Large Cell Lymphoma6CGI;CTD_human
TgeneC0334121Inflammatory Myofibroblastic Tumor4CGI;CTD_human;ORPHANET
TgeneC0018199Granuloma, Plasma Cell3CTD_human
TgeneC0007621Neoplastic Cell Transformation2CTD_human
TgeneC0027627Neoplasm Metastasis2CTD_human
TgeneC0238463Papillary thyroid carcinoma2ORPHANET
TgeneC0001973Alcoholic Intoxication, Chronic1PSYGENET
TgeneC0006118Brain Neoplasms1CGI;CTD_human
TgeneC0006142Malignant neoplasm of breast1CTD_human
TgeneC0007134Renal Cell Carcinoma1CTD_human
TgeneC0011570Mental Depression1PSYGENET
TgeneC0011581Depressive disorder1PSYGENET
TgeneC0027643Neoplasm Recurrence, Local1CTD_human
TgeneC0036341Schizophrenia1PSYGENET
TgeneC0079744Diffuse Large B-Cell Lymphoma1CTD_human
TgeneC0085269Plasma Cell Granuloma, Pulmonary1CTD_human
TgeneC0153633Malignant neoplasm of brain1CGI;CTD_human
TgeneC0278601Inflammatory Breast Carcinoma1CTD_human
TgeneC0279702Conventional (Clear Cell) Renal Cell Carcinoma1CTD_human
TgeneC0496899Benign neoplasm of brain, unspecified1CTD_human
TgeneC0678222Breast Carcinoma1CTD_human
TgeneC0750974Brain Tumor, Primary1CTD_human
TgeneC0750977Recurrent Brain Neoplasm1CTD_human
TgeneC0750979Primary malignant neoplasm of brain1CTD_human
TgeneC1257931Mammary Neoplasms, Human1CTD_human
TgeneC1266042Chromophobe Renal Cell Carcinoma1CTD_human
TgeneC1266043Sarcomatoid Renal Cell Carcinoma1CTD_human
TgeneC1266044Collecting Duct Carcinoma of the Kidney1CTD_human
TgeneC1306837Papillary Renal Cell Carcinoma1CTD_human
TgeneC1332079Anaplastic Large Cell Lymphoma, ALK-Positive1ORPHANET
TgeneC1458155Mammary Neoplasms1CTD_human
TgeneC1527390Neoplasms, Intracranial1CTD_human
TgeneC2931189Neural crest tumor1ORPHANET
TgeneC3899155hereditary neuroblastoma1GENOMICS_ENGLAND
TgeneC4704874Mammary Carcinoma, Human1CTD_human